From The Economic Times · PTI · · 1m 10s
Dr Lal PathLabs Acquires SN Genelab Stake
Dr Lal PathLabs to buy 70% stake in SN Genelab for Rs 168 crore.
In brief
Dr Lal PathLabs to buy 70% stake in SN Genelab for Rs 168 crore. Dr Lal PathLabs acquires 70% stake in SN Genelab for Rs 168 crore to boost genomic diagnostic services. Originally reported by The Economic Times.
Dr Lal PathLabs Announces Stake Acquisition
Dr Lal PathLabs Ltd said its board approved a 70 per cent stake acquisition in Gujarat-based SN Genelab for about Rs 168 crore.
Transaction Includes Performance Earn-Out
The deal features a performance-linked earn-out capped at Rs 31.5 crore, as per the regulatory filing.
SN Genelab Becomes Subsidiary
Following the acquisition, SN Genelab will become a subsidiary of Dr Lal PathLabs.
Dr Lal PathLabs Goals for Genomics
Dr Lal PathLabs aims to strengthen its genomics expertise and broaden advanced diagnostic services portfolio.
Transaction Completion Deadline
The transaction is expected to be completed by November 30, 2026, according to the filing.
SN Genelab Financial Performance
SN Genelab reported turnover of Rs 57.96 crore in FY26 versus Rs 53.36 crore in FY25 and Rs 43.27 crore in FY24.
The essence
Dr Lal PathLabs acquires 70% stake in SN Genelab for Rs 168 crore to boost genomic diagnostic services.
